Skip to content

Alumis Inc. ALMS Impairment Charges

Impairment Charges at other companies

Amgen logo
AmgenAMGN
$0-100%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$1K

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.17B+739%

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:ImpairmentOfLongLivedAssetsHeldForUse.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s impairment charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s impairment charges?
Alumis Inc. (ALMS) reported impairment charges of $444K in Q1 2026.
How has Alumis Inc.'s impairment charges changed year-over-year?
Alumis Inc.'s impairment charges increased by 235.7% year-over-year, from $132.25K to $444K.
What does impairment charges mean?
Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.